Skip to main content
AKBA logo

AKBA · Akebia Therapeutics, Inc.

Track AKBA — free
$0.42 +0.01 (+3.28%) At close · Nov 19
Market Cap
$117.26M
Shares
277.66M
Volume · Nov 19 2.75M Avg daily vol (3M) 8.17M

Price & Indicators

 

Key stats

Close
$0.42
Open
$0.40
Day range
$0.40–0.43
52-week closing range
$0.40–1.70
Average volume, 30 days
8.4M
Short interest
27.2M · 9.8% of shares · 3.0 days
Short volume, last session
56%
Last earnings
Nov 5, 2026
Latest filing
10-Q · Nov 5
Price history
Jan 2020 to Nov 2026

Up next

Feb 25, 2027 Est · unconfirmed · in 14 wks

Latest documents

2026
Nov 16
Current report 8-K Events of Nov 12
$60.0 million funded, $55.0 million loan repaid

Akebia Therapeutics entered a term loan facility with Symbiotic Capital on November 12, 2026. It funded a $60.0 million tranche, repaid its $55.0 million BlackRock loan in full, and may request up to $80.0 million more, subject to lender discretion.

Entered into a material agreement, Ended a material agreement, New debt or off-balance-sheet obligation, Unregistered sale of equity, Regulation FD disclosure, Other events
2 source passages
The Symbiotic Loan Facility closed on November 12, 2026. Akebia used the proceeds from the initial tranche to repay in full its $55.0 million loan facility with BlackRock. The Symbiotic Loan Facility consists of an initial tranche of $60.0 million that was fully funded at closing and the ability to request up to an additional $80.0 million, which Symbiotic Capital may fund at its discretion. Open the document at this passage
Nov 5
Earnings call
Vafcio reaches 11,500 patients as VOICE shows 10% fewer hospitalizations

Akebia reported $36.9 million in Q3 revenue, a $14.4 million net loss and $159.3 million cash, while Vafcio reached about 11,500 patients and VOICE showed 10% fewer hospitalizations than ESAs.

7 source passages
Akebia's third quarter 2026 financial results and business updates conference call. Last quarter, the number of patients on Vafcio increased to about 11,500 patients on therapy, representing about 20% of patients treated for anemia within these three dialysis organizations. The data demonstrated that hospitalizations were 10% lower in patients treated with Vatidustat versus ESA, without a significant difference in mortality rates. Total revenues decreased to $36.9 million in Q326 from $58.8 million in Q325. We generated a net loss of $14.4 million in Q326 versus net income of $0.5 million in Q325, driven by this quarter's lower revenues, which was partially offset by lower operating expenses, which included a $1.3 million restructuring charge incurred this quarter. We remain in a strong financial position with $159.3 million in cash-in-cash equivalents at the end of the quarter, which includes $6.6 million in ATM proceeds raised early in the quarter. There has never been an outcome study performed before VOICE that compared treatments for patients with anemia due to CKD that demonstrated an outcomes difference. Open the document at this passage
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Generic competition drives revenue decline

Akebia Therapeutics, Inc. reported product revenue of $133.6 million and a net loss of $32.3 million for the nine months ended September 30, 2026. Lower Auryxia revenue from reduced pricing and sales volume amid generic competition drove the decline.

Revenue $36.9M ▼ 37.2% Net loss $14.35M Diluted EPS -$0.05
Read from the MD&A section
5 source passages
Akebia Therapeutics, Inc. | Form 10-Q | Page 33 Net product revenue was $133.6 million for the nine months ended September 30, 2026, compared to $173.0 million for the nine months ended September 30, 2025. The decrease was primarily due to lower Auryxia revenues, which were partially offset by higher Vafseo revenues. The lower Auryxia revenues are due to a decrease in net price as well as a decrease in sales volume of Auryxia due to generic competition as described in greater detail above. We incurred a net loss of $14.4 million and $32.3 million during the three and nine months ended September 30, 2026, respectively, and generated net income of $0.5 million and $6.9 million during the three and nine months ended September 30, 2025, respectively. Open the document at this passage
Nov 5
Current report 8-K
Vafseo revenue holds amid quarterly net loss

Akebia Therapeutics reported $36.9 million in Q3 2026 revenue and a $14.4 million net loss, while Vafseo net product revenue reached $14.8 million with approximately 11,500 active patients and $159.3 million in cash.

Financial results
4 source passages
Total revenues were $36.9 million in the third quarter of 2026 compared to $58.8 million in the third quarter of 2025. Net loss was $14.4 million in the third quarter of 2026 compared to net income of $0.5 million in the third quarter of 2025. Vafseo net product revenues were $14.8 million in Q3. Approximately 11,500 patients were active on Vafseo at the end of Q3 2026, representing an approximate 8.1% increase from the end of Q2 2026 and an increase of approximately 140% over Q3 2025. Cash and cash equivalents as of September 30, 2026 were approximately $159.3 million as compared to $155.5 million as of June 30, 2026. Open the document at this passage
Oct 23
Current report 8-K Events of Oct 21
Nasdaq bid price deficiency notice; compliance deadline April 19, 2027

Nasdaq notified Akebia that its stock closed below $1.00 for the last 30 consecutive business days, with no immediate effect on listing. Compliance requires closing at or above $1.00 for 10 consecutive business days by April 19, 2027.

Delisting notice or listing transfer
4 source passages
for the last 30 consecutive business days, the bid price for the Company’s common stock, par value $0.00001 per share (the “Common Stock”), had closed below $1.00 per share The Notice has no immediate effect on the listing of the Company’s Common Stock. the closing bid price of the Company’s Common Stock must be at least $1.00 per share for a minimum of 10 consecutive business days during the Initial Compliance Period the Company has an initial period of 180 calendar days, or until April 19, 2027 (the "Initial Compliance Period"), to regain compliance with the Bid Price Requirement. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$197.20M
Trailing 12 months
Net income (TTM)
−$44.56M
Trailing 12 months
Revenue growth YoY
-37.2%
Year over year
Operating margin
-15.7%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
11.8%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$108.98M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.9%
Year over year · more shares
Price change (1Y)
-73.4%
Trailing year
Short interest
9.8%
Latest settlement · 3.0 days to cover
View all 125 metrics

AI Brief

Q2 FY26 earnings call · Aug 5, 2026
Q2 FY26

TL;DR. Akebia reported strong sequential Vafseo revenue and patient growth, and announced a positive interim VOICE trial result for Vafseo versus ESAs on mortality/hospitalization, while guiding 2027 Vafseo revenue to decline on planned price cuts after loss of tadapa exclusivity; Auryxia revenue continued to fall, driving a quarterly net loss.

Bullish
  • + Vafseo Q2 net product revenue grew 34% sequentially to $21.3 million, with over 10,500 patients on therapy (a 41% sequential increase) and ~1,200 prescribers.
  • + VOICE interim analysis met stopping criteria, showing Vafseo statistically superior to ESAs on the composite of all-cause mortality and hospitalization (win odds 1.16; p=0.0016).
  • + Phase 2 basket trial of ebribafusp in IgA nephropathy, lupus nephritis, and C3 glomerulopathy initiated, with initial data expected in 2027.
  • + Vafseo IP portfolio strengthened with a new Orange Book-listed patent and a potential 5-year term extension, with portfolio expirations out to 2036.
Bearish
  • − Q2 swung to a net loss of $8.9 million from net income of $0.2 million a year ago, driven by lower revenue and higher expenses including a $1.9 million restructuring charge.
  • − Management expects 2027 Vafseo revenue to decline versus 2026 due to a planned price reduction after expected end of tadapa on December 31, 2026.
  • − Auryxia revenue fell to $25.5 million from $47.2 million year-over-year and is expected to continue declining in 2026 due to generic competition and pricing pressure.
  • − R&D expense rose to $14.1 million from $11.0 million year-over-year on higher clinical activity and headcount costs.
  • − Total revenue declined to $49.1 million from $62.5 million year-over-year due to lower Auryxia revenue.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Bearish Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 28.4 · fear Equity put/call 0.72
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −61%
below
Price vs 50-day avg −42%
below
RSI (14) 35
neutral
MACD trend Negative
52-week position 2%
near low
Momentum
relative strength
Very Weak
1-month return −25%
trailing
6-month return −59%
trailing
YTD return −74%
this year
Relative strength −53%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Distributing
-8% holders QoQ · +22 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
9.80% of shares out · ▲ +17.9% MoM · 3.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
158 holders — mid 3-yr range
Squeeze score 62
elevated · 0–100
Fundamentals
Excellent
EPS growth +94%
Y/Y
Free cash flow $67.7M
Balance sheet $136.6M
net cash
Quant / Vol
risk profile
Very High
Volatility 90%
annualized · 1-yr
Max drawdown −76%
past year
ATR 15.8%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed Nov 5, 2026
Average annual cost of therapy · 2027 and beyond $1,000 – $1,500
Prior guidance period ended · from the 8-K filed Jan 12, 2026
Vafseo net product revenue · Q4 2025 $5M – $6M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 2 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−61% Bearish
Price vs 50-day avg
−42% Bearish
RSI (14)
35 Neutral
MACD trend
Negative Bearish
52-week position
2% Bearish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Distributing
-8% holders QoQ · +22 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
9.80% of shares out · ▲ +17.9% MoM · 3.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
158 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $0 Now $0 · 2% Range high $2
vs 200-day avg -61% vs 50-day avg -42%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Patients on Vafseo 11,500 end of Q3 2026 —
Total number of prescribers 1,300 Q3 2026 —
patients on Vafseo therapy 10,500 Q2 2026 —
prescribers 1,200 Q2 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
AKBA
Akebia Therapeutics, Inc.
this stock
$117.26M -73.8% +47.5% — 9.8%
TAK
Takeda Pharmaceutical Co Ltd
$68.40B +37.3% — — 0.1%
GALDY
Galderma Group AG
$50.89B +5.3% — — 0.0%
TEVA
Teva Pharmaceutical Industries Ltd
$44.97B +23.5% +4.3% 87.6 2.4%
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
$40.66B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
158
% held
39.2%
Net QoQ
+845.2K sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
138
View
Short & Settlement
Short Interest Rising
Shares short
27.2M
Days to cover
3.0d
Change
+4.1M sh
View
Short Volume
Short vol %
56%
As of
Nov 19, 2026
Short Total
View
Fails to Deliver
FTD shares
1.3K
Value
$972
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
80.9%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$236.2M
Net income (FY)
$-5.3M
EPS diluted
$-0.02
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 16, 2026
This year
21

Akebia Therapeutics entered a term loan facility with Symbiotic Capital on November 12, 2026. It funded a $60.0 million tranche, repaid its $55.0 million BlackRock loan in full, and may request up to $80.0 million more, subject to lender discretion.

View
Proposed Sales
Value
$62.2K
Shares
56.0K
Filed
Jun 29, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 5, 2026
View
Investor Relations
Latest news
Akebia Therapeutic’s Vafseo® (vad…
Published
Nov 17, 2026
View

Performance

5D 20D 120D MTD YTD
AKBA -15.2% -24.9% -58.6% -40.2% -73.8%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY -9.8% -18.6% -53.0% -35.0% -78.8%
Key facts CIK 1517022 CUSIP 00972D105 13F (30d) 157 filings 140 filers Visit website Investor relations